Mergers and acquisitions: agents for change
March 4, 2020 | AbbVie, Allergan, BMS, Baxalta, Baxter, Behavior change, Behaviour change, Bristol-Myers Squibb, Celgene, Comms, Communications, GSK, Glaxo SmithKline, Insights, M&A, Marketing, Novartis, Organisations, Pharma, Pharma industry, Shire, Strategy, Takeda, acquisition, agency, healthcare, medcomms, merger, mergers and acquisitions
Getting the best from your agency in a disruptive time
Multi-billion dollar mergers and acquisitions have always created headlines in pharma news, and it’s fair to say that the pharmaceutical industry probably experiences more of this type of activity than most others. From the $63 billion AbbVie-Allergan merger currently in play, to the BMS-Celgene merger in 2019, division sales such as the transfer of Novartis vaccines unit to GSK, or even serial shakeups such as seen for Baxter-Baxalta-Shire-Takeda, these events transform the industry landscape, reshaping pipelines and reshuffling R&D priorities. And despite providing longer-term strategic benefits, they also disrupt life inside the companies involved, with new internal structures and processes, changes to branding, and impact on corporate strategies, targets, and job security.
How might your agency help?
Every merger is unique, affecting brands, employees, and customers differently. No matter how carefully planned, mergers always create uncertainty, which can get in the way of delivering programmes that enhance brands and make a real difference for HCPs and patients.
Through experience Bedrock knows that during mergers and acquisitions, agencies can play an important role for clients. We have supported clients in the run up to the merger or acquisition by analysing the strategic impact of the union on a brand, and the likely opportunities and threats that might arise. During the period of any merger, it is useful to audit materials and to create or update style guides for consistency with new requirements. Instead of being forced to pause existing programmes, agencies can provide the continuity of expertise to keep projects moving, giving the client space to focus on internal challenges. And as a valued partner through the rocky road of acquisition and merger, a medical communications agency can also provide a valuable role in transitioning to new messaging and bringing disparate brands together under a portfolio umbrella.
Thinking differently
At Bedrock our number-one goal is to be our clients’ authentic ally, helping them avoid pitfalls, and effectively navigate opportunities and challenges. Bedrock always strive to build deep client relationships which are based on a foundation of trust, so that neither party hesitate to have important or challenging conversations when required, which can be critical during times of stress or uncertainty. Having supported a number of clients whose companies are undergoing mergers, Bedrock has gained valuable insights regarding how different organisations work in these circumstances, and believe it is important to provide a bridge with new teams and new procurement functions. We encourage clients to continue to be brave and not put programmes on hold; doing so can have repercussions for their brands, leaving them behind schedule, and behind the competition when the merger is complete.
We also work with our clients’ internal teams to support behavior change in order to leverage the opportunities brought by the merger. We run workshops for senior managers to ensure they communicate the value for each individual when going through a merger or acquisition; it is important to remember that what motivates a manager might not motivate those they manage. Without good communication, individuals will often feel unempowered and potentially frustrated by the change. Moreover, it is also important for the leadership to act as role models for the change they are seeking from their teams. As with all communications, there is great value in truly understanding your audience’s needs and motivations!
Like any period of change, pharmaceutical mergers and acquisitions can be a time of great uncertainty, but also great opportunity for both the individual and the brand. Whether you’re dealing with a merger, a disruptive new competitor, loss of exclusivity, or preparing for launch, contact Bedrock to discuss navigating change and maximising your opportunities.
This content was provided by Bedrock Healthcare Communications
Company Details
Latest Content from Bedrock Healthcare Communications
Imagine More for the reporting of consensus programme outputs
The Bedrock team reflects on the latest published guidance in the development of consensus programmes
The Power of Strong Partnerships
The Bedrock team reflects on what is critical to building strong partnerships.
Thinking creatively about patient involvement in publications
Bedrock's freethinking spirit to reimagine publications is on course to include patients in the full end to end of the publication process.
Agility – The Bedrock Way
The rapid pace of innovation, regulatory systems and consumer behaviour requires real agility by medical communication professionals. Bedrock has the agility to keep up with the pace of change and...
Bedrock Healthcare Communications is proud to accept the PMEA for Agility in Pharma Market Excellence
Recognition for a bold and imaginative approach to an actionable clinical consensus for MS patients.
MIRANDA DINI APPOINTED CHIEF OPERATING OFFICER AT RESONANT GROUP
Two additional leadership moves also strengthen management team
The value medical communications bring to phase 2/3 of drug development
Bedrock’s Head of Strategy, Derek Annan, explains why the development of successful communication requires not only planning, strategy and execution (and measurement), it also needs to be able to respond...
Bedrock expands growing strategy and scientific teams
Award-winning Bedrock Healthcare Communications adds three new starters at an exciting time of growth. Meet our new faces and find out what drew them to Bedrock.
Bedrock Healthcare Communications appoints Louise Adamson as Head of Scientific Services
Louise Adamson joins Bedrock as Head of Scientific Services to drive scientific and strategic excellence and grow and develop the scientific team.
Bedrock’s Accelerated Virtual Consensus Programme for Merck wins at Communiqué Awards
The award recognises outstanding achievement in flexing thinking and processes to ensure success.